9-ING-41 in Pediatric Patients With Refractory Malignancies.
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients.
This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.